| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
FP
FP receptor (prostaglandin F receptor). BAY-6672 is a potent and selective antagonist of the human prostaglandin F (FP) receptor. It has an IC50 of 11 nM. By blocking the FP receptor, it inhibits the activity of prostaglandin F2α (PGF2α), a key mediator of fibrosis and inflammation. This antagonism reduces pro-fibrotic signaling. |
|---|---|
| ln Vitro |
BAY-6672 is a potent FP receptor antagonist with an IC50 of 11 nM. It inhibits PGF2α activity through FP receptor antagonism. In cellular models, it would be expected to inhibit PGF2α-induced signaling, including calcium mobilization and downstream pro-fibrotic gene expression. Its selectivity for the FP receptor makes it a valuable tool for studying FP receptor function.
|
| ln Vivo |
In vivo, BAY-6672 (3, 10, 30 mg/kg, twice daily) showed antifibrotic activity in a mouse 10-day silica-induced pulmonary fibrosis model. Significant reductions in pro-fibrotic and inflammatory biomarkers, including IL-1, MCP-1, and the ECM protein osteopontin (OPN), were observed. This demonstrates its potential for treating idiopathic pulmonary fibrosis (IPF).
|
| Enzyme Assay |
In vitro receptor binding and functional assays are used to characterize BAY-6672 as an FP receptor antagonist. Radioligand binding assays or functional assays measuring inhibition of PGF2α-induced signaling, such as calcium mobilization, are performed using cells expressing the FP receptor to determine its IC50 of 11 nM.
|
| Cell Assay |
Cellular assays for BAY-6672 involve treating FP receptor-expressing cells with the compound and measuring inhibition of PGF2α-induced responses. Functional readouts include inhibition of calcium mobilization or downstream signaling pathways. These assays confirm the compound's antagonistic activity and potency at the FP receptor.
|
| Animal Protocol |
In vivo efficacy of BAY-6672 is evaluated in animal models of pulmonary fibrosis. In a mouse 10-day silica-induced pulmonary fibrosis model, BAY-6672 (3, 10, 30 mg/kg, twice daily) showed antifibrotic activity. Efficacy endpoints include reduction of pro-fibrotic and inflammatory biomarkers such as IL-1, MCP-1, and osteopontin.
|
| ADME/Pharmacokinetics |
BAY-6672 has a molecular formula of C26H27BrClN3O3 and a molecular weight of 544.87. It is orally available with good permeability. As a small-molecule FP receptor antagonist, its pharmacokinetic properties support oral dosing. The compound has a purity of ≥98% and should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for BAY-6672. As an FP receptor antagonist, its safety profile would be an important consideration for therapeutic applications. Potential toxicities could be related to its effects on PGF2α-mediated signaling in various tissues. Standard preclinical safety studies would be required to evaluate its safety.
|
| References | |
| Additional Infomation |
BAY-6672 (CAS#: 2247517-53-7) is a potent and selective human prostaglandin F (FP) receptor antagonist with an IC50 of 11 nM. It is orally available and has demonstrated antifibrotic activity in animal models of idiopathic pulmonary fibrosis. It has a molecular formula of C26H27BrClN3O3 and a molecular weight of 544.87. It is a research tool for studying FP receptor function and fibrosis.
|
| Molecular Formula |
C26H27BRCLN3O3
|
|---|---|
| Molecular Weight |
544.87
|
| Exact Mass |
543.092
|
| CAS # |
2247517-53-7
|
| Related CAS # |
BAY-6672 hydrochloride;2247520-31-4
|
| PubChem CID |
146368333
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
34
|
| Complexity |
707
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl
|
| InChi Key |
YQOLEILXOBUDMU-KRWDZBQOSA-N
|
| InChi Code |
InChI=1S/C26H27BrClN3O3/c1-16-24(20-14-18(27)9-10-22(20)30-25(16)31-12-4-5-13-31)26(34)29-15-17(8-11-23(32)33)19-6-2-3-7-21(19)28/h2-3,6-7,9-10,14,17H,4-5,8,11-13,15H2,1H3,(H,29,34)(H,32,33)/t17-/m0/s1
|
| Chemical Name |
(4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8353 mL | 9.1765 mL | 18.3530 mL | |
| 5 mM | 0.3671 mL | 1.8353 mL | 3.6706 mL | |
| 10 mM | 0.1835 mL | 0.9177 mL | 1.8353 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
